Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Hannah Daikeler"'
Autor:
Philipp Erben, Stefan W. Krause, Hans J. Kolb, Wolf-Karsten Hofmann, Dominik Heim, Martin C. Mueller, Hermann Heimpel, Mridul Agrawal, Armin Leitner, Jörg Hasford, Rüdiger Hehlmann, Hans Pralle, Benjamin Hanfstein, D. K. Hossfeld, Juliana Popa, Hannah Daikeler, Andreas Hochhaus, Umang Munjal, Gabriela M. Baerlocher, Daniel Nowak, Christoph Nerl, Susanne Saussele
Publikováno v:
Blood. 116:671-671
Abstract 671 Introduction: The goal of imatinib therapy in newly diagnosed CML patients is the rapid achievement of cytogenetic and molecular responses. However, suboptimal response or resistance occur in a significant proportion of patients. BCR-ABL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e985768d6bf39fbe7d49eb37c880293
https://doi.org/10.1182/blood.v116.21.671.671
https://doi.org/10.1182/blood.v116.21.671.671
Autor:
Andreas Hochhaus, Armin Leitner, Juliana Popa, Benjamin Hanfstein, Thomas Schenk, Richard C. Woodman, Philipp Erben, Mridul Agrawal, Martin Müller, Hannah Daikeler
Publikováno v:
Blood. 114:2615-2615
Abstract 2615 Poster Board II-591 Introduction: The majority of patients with chronic myeloid leukemia (CML) in chronic phase achieve and maintain complete cytogenetic remission after frontline therapy with imatinib mesylate. In case of resistance or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb7f442214d9314ce2198945c3526783
https://doi.org/10.1182/blood.v114.22.2615.2615
https://doi.org/10.1182/blood.v114.22.2615.2615